Australian drug chosen for global trial to treat COVID-19

All LIT Search News Topics Latest news Media statements Media contacts Topics Latest news Media statements Media contacts LIT Impact Latest news 2020 June Australian drug chosen for global trial to treat COVID-19 Australian drug chosen for global trial to treat COVID-19 04/06/2020 | 3 MINS The drug, known as DMX-200, was chosen as part of the Randomised, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) program, which is endorsed by the World Health Organisation and designated a Pandemic Special Study. REMAP-CAP is an international platform trial run by a network of leading experts, institutions, and research groups. The program is studying a number of interventions to treat people hospitalised with proven or suspected COVID-19, in ICU and non-ICU settings. The overall REMAP-CAP study plans to include more than 7,000 patients from over 200 study sites across Asia-Pacific, Europe and North America. It already has treatments in the anti-viral, immune-modulation and immunoglobulin sphere, and biopharmaceutical company Dimerix is part of a new treatment group. Professor Kevin Pfleger, Chief Scientific Advisor to Dimerix, welcomed the announce

All LIT Search News Topics Latest news Media statements Media contacts Topics Latest news Media statements Media contacts LIT Impact Latest news 2020 June Australian drug chosen for global trial to treat COVID-19 Australian drug chosen for global trial to treat COVID-19 04/06/2020 | 3 MINS The drug, known as DMX-200, was chosen as part of the Randomised, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) program, which is endorsed by the World Health Organisation and designated a Pandemic Special Study.

REMAP-CAP is an international platform trial run by a network of leading experts, institutions, and research groups.

We do more when we ask better questions together.